About calithera biosciences - CALA
Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
CALA At a Glance
Calithera Biosciences, Inc.
343 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-870-1000 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -21,290,000.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
CALA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.364 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.112 |
CALA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,129,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CALA Liquidity
| Current Ratio | 3.603 |
| Quick Ratio | 3.603 |
| Cash Ratio | 3.444 |
CALA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -45.573 |
| Return on Equity | -147.981 |
| Return on Total Capital | -96.518 |
| Return on Invested Capital | -59.738 |
CALA Capital Structure
| Total Debt to Total Equity | 8.17 |
| Total Debt to Total Capital | 7.553 |
| Total Debt to Total Assets | 5.81 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 0.617 |